MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
06 December 2021 - 10:05PM
MannKind Corporation (Nasdaq: MNKD), a
company focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that it will be participating in the
Lytham Partners Winter 2021 Investor Conference taking place from
December 13-16, 2021. During the event, the Company’s Chief
Executive Officer, Michael Castagna, PharmD, will be participating
in a webcasted Fireside Chat discussing its vision for 2022 and Mr.
Castagna and the Company’s Chief Financial Officer, Steven B.
Binder will be conducting 1x1 virtual investor meetings.
The webcasted Fireside Chat will be available for viewing at
11:00 AM ET on Monday, December 13, 2021, on the Company's website
at https://investors.mannkindcorp.com/events-and-presentations. The
webcast will also be archived and available for replay.
To arrange a 1x1 meeting with management, please contact Lytham
Partners at 1x1@lythampartners.com or register at
www.lythampartners.com/winter2021invreg.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
MANNKIND CONTACT:
Rose Alinaya, Investor Relations(818) 661-5000Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2024 to May 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From May 2023 to May 2024